Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Peter J. Allen

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108078524; NIH RePORTER profile ID 8876021. Sources: ClinicalTrials.gov.

Their work

Papers
46 (first author 1, last author 12)
Trials
2 (principal investigator on 2)
Grants
4
Labs led
2
Collaborators
182
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: 1 trial · 2010: none · 2011: 6 papers · 2012: 5 papers, 1 grant · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 6 papers · 2017: 8 papers · 2018: 7 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 grant · 2022: 2 papers · 2023: 1 grant · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper, 1 grant

Papers 46

  1. Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.11.001↗
  2. A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. Co-author DOI 10.1007/s00262-025-04146-5↗
  3. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  4. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  5. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  6. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  7. ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0529↗
  8. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  9. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  10. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? Co-author DOI 10.1016/j.clcc.2018.01.009↗
  11. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Last author DOI 10.1016/j.hpb.2017.09.001↗
  12. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Co-author DOI 10.1016/j.hpb.2017.12.010↗
  13. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  14. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  15. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. First author DOI 10.3390/cancers10030067↗
  16. The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. Co-author DOI 10.1007/s10552-017-0933-8↗
  17. ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jacr.2017.08.050↗
  18. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Co-author DOI 10.1038/nature24462↗
  19. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Co-author DOI 10.1080/0284186x.2016.1245862↗
  20. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarc… Co-author DOI 10.1097/sla.0000000000001763↗
  21. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  22. Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5757-3↗
  23. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0188022↗
  24. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.24125↗
  25. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Last author DOI 10.1007/s11605-015-3057-z↗
  26. Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. Co-author DOI 10.1016/j.clinimag.2016.08.011↗
  27. Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. Co-author DOI 10.1016/j.ebiom.2016.03.043↗
  28. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  29. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  30. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  31. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-015-4647-4↗
  32. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. Co-author DOI 10.1371/journal.pone.0139049↗
  33. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. Co-author DOI 10.1371/journal.pone.0094928↗
  34. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Last author DOI 10.1007/s11605-012-2071-7↗
  35. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Last author DOI 10.1111/hpb.12033↗
  36. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? Last author DOI 10.1111/j.1477-2574.2012.00477.x↗
  37. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Last author DOI 10.1245/s10434-011-1900-3↗
  38. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Last author DOI 10.1245/s10434-011-2156-7↗
  39. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-012-2301-y↗
  40. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Last author DOI 10.1371/journal.pone.0040157↗
  41. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Co-author DOI 10.1038/ajg.2011.65↗
  42. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcin… Last author DOI 10.1097/sla.0b013e318214bcb4↗
  43. Serum biomarker panels for the detection of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0248↗
  44. Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-010-1372-x↗
  45. Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be. Co-author DOI 10.1245/s10434-011-2089-1↗
  46. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Co-author DOI 10.1634/theoncologist.2011-0185↗

Trials 2

  1. Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess Principal investigator NCT00994110↗
  2. Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery Principal investigator NCT00536874↗

Grants 4

  1. Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas R01CA182076↗
  2. Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) R01CA235677↗
  3. Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers U01CA152653↗
  4. Antibody bead array technology for diagnosis of pre-invasive pancreatic cancer R21CA158267↗

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William R. Jarnagin · 22 shared papers, 2011–2022 · strength 1.25
  2. Michael Ian D'Angelica · 19 shared papers, 2011–2022 · strength 1.12
  3. T. Peter Kingham · 15 shared papers, 2012–2022 · strength 1.04
  4. Carlos Fernandez-Del Castillo · 1 shared grant, 2026 · strength 1.00
  5. Christopher L. Wolfgang · 1 shared grant, 2026 · strength 1.00
  6. Vinod P. Balachandran · 9 shared papers, 2017–2022 · strength 0.74
  7. Eileen Mary O'Reilly · 11 shared papers, 1 shared trial, 2007–2022 · strength 0.69
  8. Randall E. Brand · 3 shared papers, 1 shared grant, 2011–2021 · strength 0.55
  9. Julia Button · 2 shared papers, 2025–2026 · strength 0.53
  10. Elishama N. Kanu · 2 shared papers, 2025–2026 · strength 0.53
  11. Ethan S. Agritelley · 2 shared papers, 2025–2026 · strength 0.53
  12. Daniel P. Nussbaum · 2 shared papers, 2025–2026 · strength 0.53
  13. Kenneth H. Yu · 6 shared papers, 2011–2022 · strength 0.48
  14. Richard Kinh Gian · 6 shared papers, 2015–2022 · strength 0.47
  15. Jeffrey A. Drebin · 5 shared papers, 2015–2022 · strength 0.45
  16. Brian B. Haab · 1 shared grant, 2021 · strength 0.44
  17. Yuman Fong · 11 shared papers, 2011–2016 · strength 0.42
  18. Amber L. Simpson · 5 shared papers, 2017–2022 · strength 0.42
  19. Caitlin A. McIntyre · 4 shared papers, 2019–2022 · strength 0.41
  20. Olca Baştürk · 6 shared papers, 2017–2019 · strength 0.36
  21. Christine A. Iacobuzio–Donahue · 5 shared papers, 2017–2020 · strength 0.35
  22. Jayasree Chakraborty · 4 shared papers, 2017–2022 · strength 0.34
  23. Ryne C. Ramaker · 1 shared paper, 2026 · strength 0.33
  24. Murray F. Brennan · 8 shared papers, 2011–2016 · strength 0.26
  25. Anna M. Varghese · 3 shared papers, 2017–2022 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.